CTOs on the Move

Tarsus Pharmaceuticals

www.tarsusrx.com

 
Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities, initially in ophthalmic conditions, where there are limited treatment alternatives. It is advancing its pipeline to address several diseases across therapeutic categories including eye care, dermatology, and other diseases with high, unmet needs. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of Demodex blepharitis.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.tarsusrx.com
  • 15440 Laguna Canyon Road Suite 160
    Irvine, CA USA 92618
  • Phone: 949.409.9820

Executives

Name Title Contact Details

Funding

Tarsus Pharmaceuticals raised $60M on 01/08/2020
Tarsus Pharmaceuticals raised $75.6M on 05/03/2022

Similar Companies

IriSys Inc

IriSys Inc is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Rimsys Regulatory Management Software

Learn about the first and only holistic Regulatory Information Management (RIM) software for medical device companies that consolidates all the functions of regulatory affairs.

Fuse Medical

Fuse Medical, Inc., formerly Golf Rounds.com, Inc., is engaged in marketing, distributing and selling internal fixation, bone materials, biologics, tissues, surgical and other related surgical products. The Company operates through medical products and...

Family Discount Pharmacy

Family Discount Pharmacy is a Carmichael, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Enanta

Enanta Pharmaceuticals is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Two protease inhibitors, glecaprevir and paritaprevir, discovered and developed through Enanta`s collaboration with AbbVie, have now been approved around the world as part of AbbVie`s regimens for the treatment of hepatitis C virus (HCV) infection. The leading regimen is sold under the tradenames MAVYRET™ (U.S.) and MAVIRET™ (ex-U.S.) (glecaprevir/pibrentasvir). Royalties from the AbbVie collaboration are helping to fund Enanta`s research and development efforts, which are currently focused on the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV), SARS-CoV-2 (COVID-19) and human metapneumovirus (hMPV).